Thus, although 124I- and 89Zr-girentuximab have proven value in distinguishing benign from malignant renal lesions, as well as in detecting and monitoring primary and metastatic sites of ccRCC, future studies should focus on new MI agents (e.g., low-molecular-weight agents) targeting CAIX to overcome current limitations. The gene discussed is CA9; the disease is nonpapillary renal cell carcinoma.